The purpose of this open study was to find out whether botulinum toxin A (BTX-A) relieves the signs and symptoms of chronic limb spasticity. The study comprised 40 patients, aged 12-82 years, with moderate to severe spasticity of the upper (13) or lower limbs (27) refractory to conventional physical and medical treatments. Outcome measures were clinical and blinded videotape assessments of spasticity and motor function. Electromyography guided BTX-A injections were given in one or two sessions at total doses averaging 175 U in the upper limb (range 70-270 U) and 221 U in the lower limb (range 100-500 U). Thirty four patients (85%) derived worthwhile benefit, with improved limb posture and increased range of passive motion in 31, pain reduction in 28 of 31 with pain, and improved function in 16. Side effects were limited to local and usually mild discomfort from the injections (19), symptomatic local weakness (one), and local infection (one). Preliminary experience indicates that BTX-A is a promising adjunctive treatment for selected patients with spasticity. ( Neurol Neurosurg Psychiatry 1995:58;232-235) 
Spasticity is a velocity dependent increase in muscle resistance to stretch. The term is often extended to include the associated features of exaggerated tendon reflexes, clonus, and flexor spasms,' 2 and it is in this context that we use it.
The mainstay of treatment remains physiotherapy, but Botulinum toxin A (BTX-A) produces dose related weakness of skeletal muscle by impairing the release of acetylcholine at the neuromuscular junction. Although shown to be a safe and effective treatment for dystonia,3 so far few studies have explored the potential of BTX-A in the treatment of spasticity.4-9
The purpose of this open study was to find out whether BTX-A relieves the signs and symptoms of chronic limb spasticity that were refractory to other treatments.
Methods
Patients were recruited from neurology outpatients or inpatients of the Royal Perth and Royal Perth Rehabilitation Hospitals, after having given their informed consent to participation. Subject entry criteria were moderate to severe spasticity (based on the modified Ashworth spasticity scale) of at least six months' duration with a static or slowly progressive course; refractoriness to conventional physical and medical treatments; specific target muscle(s) enabling practical treatment by local injections; and no change in antispasticity treatment over the trial period. Exclusion criteria were major contractures of target muscles; other chronic disease causing major physical disability in the target region(s) (for example, rheumatoid arthritis); and pregnancy or nursing mothers.
Each patient was assessed by an experienced neurophysiotherapist, a neurologist, and a blinded medical observer, who viewed randomly arranged videotapes performed with a standard protocol. Two baseline assessments were performed three to four weeks apart primarily to ensure stability of signs, but also to monitor the reliability of the assessment procedures. At least two further assessments were performed, four to six weeks and four to six months after injections. Modified motor assessment (parts A-C): Part A: active movement subscale (involved limb) Upper limb (score 0-57) n = 13 5-4 (6-1) 6-3 (5-9) 8-0 (7 9) NS Lower limb (score 0-36) n = 27 8-9 (6 7) 10-1 (7-1) 12-1 (7-7) 0-004 Part B: rapid movement subscale (score 0-12): 3-7 (2 6) 3-7 (2-7) 3-7 (2 7) NS Part C: mobility subscale (score 0-27):
Upper limb treated n = 13
16-5 (9 3) 16-6 (9-3) 16-6 (9 3) NS Lower limb treated n = 27 14-4 (9-6) 14-4 (9-7) 17-6 (8 3) 0-007 Passive range of joint motion (goniometer):
78 (53) 80 ( tion coefficients were 0-79-1 0 (p < 0 004). Improvements after treatment were seen in most outcome measures, these all being related to changes in the treated muscles. Overall a worthwhile benefit occurred in 34 patients (85%), with an increased range of passive motion in 31, pain reduction in 28 of 31 with pain, and improved function in 16. The mean change in the modified Ashworth spasticity score at the site of treatment was 1-2 (95% confidence interval (95% CI) 1-0-1 -4) and in the spasm frequency scale it was 2-4 (95% CI 2 0-2 7). Lindmark's modified motor assessment system showed changes confined to the injected limb, so Overall, 34 patients (85%) had a worthwhile benefit. In all cases this was directly attributable to weakening of the muscle injected, although another mechanism such as selective effects on fusimotor fibres may have contributed. Improvement occurred irrespective of the underlying cause of spasticity. Even the two patients with motor neuron disease had worthwhile benefit without side effects. Likewise the degree of benefit did not correlate with the duration of spasticity; indicating that BTX-A can be used to treat longstanding spasticity as long as fixed contractures have been avoided. This study has the limitations of any open trial. Whereas we have considered observer bias with blinded videotape assessments, the patient was not blinded to treatment. The promise of this study is that most of these patients, refractory to other treatments, benefited substantially. All improvements were confined to target muscles, and spasticities of untreated regions in the same and other limbs were unchanged from the baseline measurements. The EMG findings and time course of benefit were consistent with a BTX-A effect, and the benefit has been reproducible in the 22 patients who have had repeat treatment so far. It is important to emphasise that the patients treated were carefully selected, based on (a) the presence of specific and localised target muscles allowing this intervention to be 
